Recent developments in the assessment of Alzheimer's disease (AD) have centered on differential diagnostic questions. Only a few studies have aimed to identify neuropsychological measures that allow the prediction of disease progression. However, this question is central to informing patients about their diagnosis and to decisions regarding the urgency and timing of treatment escalation.
Objective
We analyzed which, if any, neuropsychological test results reflect the extent of neurodegenerative progression.
Methods
This retrospective analysis included 290 patients divided into an Aβ-ratio + group (n = 146; AD biomarker profile) and an Aβ-ratio– group (n = 144; non-AD biomarker profile). The Aβ-ratio + group was further divided into four t-tau quartiles. The Aβ-ratio– group was subdivided into patients with normal (n = 94) or elevated t-tau (n = 50).
Results
Regression and variance analyses demonstrated a correlation between Trail Making Test B (TMT-B) performance and t-tau levels in patients with an Aβ-ratio+, driven by differences between low and high tau values, but not in Aβ-ratio– patients. Several additional statistical control analyses endorsed this finding.
Conclusions
We conclude that, for Aβ-ratio + patients, TMT-B performance may serve as a clinically accessible indicator of tau-related disease activity and the extent of neurodegeneration and may help identify patients at risk of faster progression if replicated in longitudinal studies.
BraakHBraakE. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging1997; 18: S85–S88.
2.
BraakHDel TrediciK. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain2015; 138: 2814–2833.
3.
DuboisBVillainNFrisoniGB, et al.Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol2021; 20: 484–496.
4.
JackCRJrBennettDABlennowK, et al.NIA-AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
5.
DragoVBabiloniCBartres-FazD, et al.Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. J Alzheimers Dis2011; 26: 159–199.
6.
DuboisBAlbertML. Amnestic MCI or prodromal Alzheimer's disease?Lancet Neurol2004; 3: 246–248.
7.
YeungLKOlsenRKHongB, et al.Object-in-place memory predicted by anterolateral entorhinal cortex and parahippocampal cortex volume in older adults. J Cogn Neurosci2019; 31: 711–729.
8.
DarmantheNTabatabaei-JafariHCherbuinN, et al.Combination of plasma neurofilament light chain and Mini-Mental State Examination score predicts progression from mild cognitive impairment to Alzheimer's disease within 5 years. J Alzheimers Dis2021; 82: 951–964.
9.
Mattsson-CarlgrenNLeuzyAJanelidzeS, et al.The implications of different approaches to define AT(N) in Alzheimer disease. Neurology2020; 94: e2233–e2244.
10.
RadanovicMOshiroCAFreitasTQ, et al.Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort. Braz J Psychiatry2019; 41: 479–484.
11.
TannerJARabinoviciGD. Relationship between tau and cognition in the evolution of Alzheimer's disease: new insights from tau PET. J Nucl Med2021; 62: 612–613.
12.
TherriaultJPascoalTALussierFZ, et al.Biomarker modeling of Alzheimer's disease using PET-based Braak staging. Nat Aging2022; 2: 526–535.
LinYTChengJTYaoYC, et al.Increased total tau but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease. J Alzheimers Dis2009; 18: 907–918.
15.
RamiLForteaJBoschB, et al.Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. J Alzheimers Dis2011; 23: 319–326.
16.
TimmersMTesseurIBogertJ, et al.Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. Neurobiol Aging2019; 79: 131–141.
17.
HildebrandtHHaldenwangerAElingP. False recognition correlates with amyloid-beta (1-42) but not with total tau in cerebrospinal fluid of patients with dementia and mild cognitive impairment. J Alzheimers Dis2009; 16: 157–165.
18.
ReijsBLRRamakersIKohlerS, et al.Memory correlates of Alzheimer's disease cerebrospinal fluid markers: a longitudinal cohort study. J Alzheimers Dis2017; 60: 1119–1128.
19.
FowlerKSSalingMMConwayEL, et al.Paired associate performance in the early detection of DAT. J Int Neuropsychol Soc2002; 8: 58–71.
20.
VromenEMde LeeuwDMvan HartenAC, et al.CSF Proteomic profiles related to cognitive decline in MCI A+ depend on tau levels. Brain2025; 148: 4389–4399.
21.
VromenEMLagemanSBGobomJ, et al.Cerebrospinal fluid proteomic associations of APOE genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease. Alzheimers Dement2025; 21: e70738.
22.
WuestefeldAXieLMcGrewE, et al.Tau, atrophy, and domain-specific cognitive impairment in typical Alzheimer's disease. Alzheimers Dement2025; 21: e70511.
23.
GiuffreGMQuarantaDCitroS, et al.Associations between Free and Cued Selective Reminding Test and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. J Alzheimers Dis2024; 100: 713–723.
24.
FillenbaumGGMohsR. CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 years and counting. J Alzheimers Dis2023; 93: 1–27.
25.
MorrisJCMohsRCRogersH, et al.Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull1988; 24: 641–652.
26.
SchmidNSEhrenspergerMMBerresM, et al.The extension of the German CERAD neuropsychological assessment battery with tests assessing subcortical, executive and frontal functions improves accuracy in dementia diagnosis. Dement Geriatr Cogn Dis Extra2014; 4: 322–334.
27.
WechslerD. Wechsler Memory Scale – Revised. New York: The Psychological Corporation, 1987.
FolsteinMFRobinsLNHelzerJE. The Mini-mental state examination. Arch Gen Psychiatry1983; 40: 812.
30.
HansenNJuhlALGrenzerIM, et al.Cerebrospinal fluid total tau protein correlates with longitudinal, progressing cognitive dysfunction in anti-neural autoantibody-associated dementia and Alzheimer's dementia: a case-control study. Front Immunol2022; 13: 837376.
31.
BonomiCGMottaCDi DonnaMG, et al.Age of onset moderates the effects of vascular risk factors on neurodegeneration, blood-brain-barrier permeability, and cognitive decline in Alzheimer's disease. Alzheimers Res Ther2024; 16: 248.
32.
CoomansEMvan WestenDBinetteAP, et al.Interactions between vascular burden and amyloid-beta pathology on trajectories of tau accumulation. Brain2024; 147: 949–960.
33.
EckhoffKMorrisRZuluagaV, et al.The association between tau protein level in cerebrospinal fluid and cognitive status: a large-scale analysis of GAAIN database. Brain Sci2021; 11: 861.
34.
CogswellPMLundtESTherneauTM, et al.Evidence against a temporal association between cerebrovascular disease and Alzheimer's disease imaging biomarkers. Nat Commun2023; 14: 3097.
